Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan

Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan

Data on the safety and efficacy of cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer (CRPC) are limited. We report the safety (adverse drug reactions [ADRs]) and efficacy (overall survival [OS], time to treatment failure [TTF], and prostate-specific antigen [PSA] respo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of geriatric oncology 2020-09, Vol.11 (7), p.1067-1073
Hauptverfasser: Matsubara, Nobuaki, Suzuki, Kazuhiro, Kazama, Hirotaka, Tsukube, Shoko, Seto, Takeshi, Matsuyama, Hideyasu
Format: Artikel
Sprache:eng
Schlagworte:
Cabazitaxel
Castration-resistant prostate cancer
Geriatric oncology
Post-marketing drug surveillance
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Data on the safety and efficacy of cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer (CRPC) are limited. We report the safety (adverse drug reactions [ADRs]) and efficacy (overall survival [OS], time to treatment failure [TTF], and prostate-specific antigen [PSA] response rates) in patients aged
ISSN:1879-4068
1879-4076
DOI:10.1016/j.jgo.2020.02.014